Gilead Sciences, Inc. $GILD is Genus Capital Management Inc.’s 7th Largest Position

Genus Capital Management Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 17.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 152,036 shares of the biopharmaceutical company’s stock after selling 31,653 shares during the quarter. Gilead Sciences makes up approximately 2.1% of Genus Capital Management Inc.’s investment portfolio, making the stock its 7th largest position. Genus Capital Management Inc.’s holdings in Gilead Sciences were worth $16,856,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in GILD. One Wealth Advisors LLC boosted its stake in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares during the last quarter. Ariel Investments LLC boosted its stake in Gilead Sciences by 7.7% during the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the last quarter. Wealth Management Associates Inc. acquired a new position in Gilead Sciences during the second quarter worth $255,000. Covea Finance boosted its stake in Gilead Sciences by 69.5% during the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after buying an additional 21,200 shares during the last quarter. Finally, Sivik Global Healthcare LLC boosted its stake in Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after buying an additional 10,000 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 71,500 shares of company stock valued at $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $123.00 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The business’s fifty day simple moving average is $115.98 and its 200-day simple moving average is $111.92. The firm has a market cap of $152.62 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the company posted $2.02 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Wolfe Research boosted their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Finally, UBS Group upped their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $125.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.